Month: August 2012

Home » Archives for August 2012

Survival Better with Continuous ADT

Intermittent androgen deprivation therapy (ADT) has some quality-of-life (QOL) benefits for men with metastatic prostate cancer, but overall survival times are inferior to those seen with continuous ADT, according to the findings of a 17-year study (SWOG9346) presented at the American Society for Clinical Oncology 2012 annual meeting. Read More.

Survival Better with Continuous ADT Read More »

Drug from Mediterranean weed kills tumor cells in mice

Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel — undetected by normal cells through the bloodstream until activated by specific cancer proteins. The drug, made from a weedlike plant, has been shown to destroy cancers and their direct blood supplies, acting like a “molecular grenade,” and sparing healthy blood vessels and tissues. Read More.

Drug from Mediterranean weed kills tumor cells in mice Read More »

Questioning Surgery for Early Prostate Cancer

A new study shows that prostate cancer surgery, which often leaves men impotent or incontinent, does not appear to save the lives of men with early-stage disease, who account for most cases, and many of these men would do just as well to choose no treatment at all. From the NY Times And a second article  

Questioning Surgery for Early Prostate Cancer Read More »

Scroll to Top